This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|November 3, 2014
Sartorius Opens New Application Center
Author(s)BioPharm International Editors
Sartorius opened a new application center at its offices in Shanghai for product demonstrations, trial runs, and training sessions.
Advertisement
Sartorius announced on Oct. 30, 2014 that it opened a new application center at its offices in Shanghai. The 2600-ft2 center will be used to demonstrate products, complete trial runs, and run training sessions.
Customers can test the latest products from Sartorius in cell cultivation, media and buffer preparation, sterile filtration, cross-flow purification, membrane chromatography, virus clearance, and aseptic processing. Laboratory customers can visit the center to see instruments and consumables: balances, moisture analyzers, pipettes, water purification systems, filters, and products for microbiological testing and quality control.
“Our application center is not just a showroom for our extensive range of lab and bioprocess products. We invite our customers to gain hands-on experience with our technologies during training and demonstration. By doing this, we can demonstrate the benefits of the high degree of seamless integration of the newest state-of-the-art technology for biotech manufacturing,” said Dr. Jörg Lindenblatt, the senior vice-president of sales Asia/Pacific for Bioprocess Solutions, in a press release.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5